YouTube Facebook LinkedIn Google+ Twitter Xinginstagram rss  

News Blast

Feb 15, 2006

Tripos announced completion of the reduction in force for its discovery research business, affecting 76 employees at its facility in Bude, England. This action was spurred on by the completion of a four-year, $90 million project with Pfizer. Through the changes, the company will continue providing services. (See Green Pastures for Discovery Informatics, May 2005 Bio•IT World, page 38.)

Dharmacon announced a settlement of its contract dispute with MIT, which has dismissed all legal claims against Dharmacon and parent company Fisher Scientific International, which in turn dismissed its counterclaims against MIT. MIT had voluntarily dropped its patent infringement claim against Dharmacon’s reverse transfection RNAi product in October 2005.

DNAPrint Genomics formed a subsidiary, DNAPrint Pharmaceuticals, to commercialize its personalized medicine products and hired as director geneticist Barbara Handelin, former director of the DNA Diagnostics Laboratory of what is now Genzyme Genetics. The Sarasota, Fla.-based company aims to use its genetics testing capabilities as predictors of how well a particular therapy might work on a patient based on physical makeup.

Click here to login and leave a comment.  


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.